Stenting of long coronary artery lesions: Initial angiographic results and 6-month clinical outcome of the micro stent II-XL

• Published in: Catheterization and cardiovascular interventions Vol. 48; no. 1; pp. 105 - 112
• Main Authors: Schalij, Martin J., Udayachalerm, Wasan, Oemrawsingh, Pranobe, Jukema, J. Wouter, Reiber, Johan H.C., Bruschke, Albert V.G.
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 01.09.1999
• Subjects: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; balloon angioplasty; Coronary Angiography; coronary artery disease; Coronary Vessels - pathology; Equipment Design; Female; Follow-Up Studies; Humans; Male; Middle Aged; stents; Stents - adverse effects
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/(SICI)1522-726X(199909)48:1<105::AID-CCD22>3.0.CO;2-0

To evaluate the results of long Micro Stent II (MS‐XL) implantations, 119 MS‐XLs were implanted in 102 patients (age, 62.83 years). Nineteen stents (16%) were implanted in saphenous vein grafts; 100 stents (84%) were implanted in native coronary arteries. Twenty‐five patients (25%) were treated because of acute myocardial infarction (AMI); 30 patients (29%) because of unstable angina or angina class IV, and 47 patients (46%) because of stable angina. Eighty‐six de novo lesions (84%) and 16 restenotic lesions (16%) were treated. Indications for stent implantation include elective, 61 patients (60%); suboptimal balloon angioplasty result, 22 patients (21%); and bailout after balloon angioplasty, 19 patients (19%). Because of residual thrombus after stenting, 27 patients (26%) received abciximab. All patients received ticlopidin for 28 days and acetylsalicylic acid. One hundred and seventeen MS‐XLs (98%) were implanted successfully. Additional (shorter) MS‐II were implanted in 40 patients (39%). The stented segment length was 45 ± 20 mm. The minimum lumen diameter increased from 0.5 ± 0.5 mm before to 2.7 ± 0.5 mm after stent implantation. The acute gain was 2.2 ± 0.4 mm. Early clinical events (<4 weeks) include death, 3 (3%); subacute stent thrombosis, 1 (1%); non–Q‐wave infarction, 2 (2%); CABG, 1 (1%); vascular complications, 2 (2%). Late clinical events (<6 months) include acute myocardial infarction, 5 (5%); reintervention, 6 (6%); CABG, 1 (1%). The procedural success rate was 88%, and the event free survival at 6 months was 76%. Stenting of long lesions with the MS‐XL was successful and associated with an acceptable complication rate. Cathet. Cardiovasc. Intervent. 48:105–112, 1999. © 1999 Wiley‐Liss, Inc.